Myelodysplastic Syndromes

Overview

Journal Clin Lab Med

Specialty Pathology

Date 2011 Nov 29

PMID 22118747

Citations 2

Authors

Olatoyosi Odenike

John Anastasi

Michelle M Le Beau

Affiliations

Soon will be listed here.

Abstract

The myelodysplastic syndromes are a diverse group of clonal stem cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias, and an increased propensity to evolve to acute myeloid leukemia. The molecular pathogenesis of these disorders is poorly understood, but recurring chromosomal abnormalities occur in approximately 50% of cases and are the focus of much investigation. The availability of newer molecular techniques has allowed the identification of additional genetic aberrations, including mutations and epigenetic changes of prognostic and potential therapeutic importance. This review focuses on the key role of cytogenetic analysis in myelodysplastic syndromes in the context of the diagnosis, prognosis, and pathogenesis of these disorders.

Citing Articles

Evaluation of and gene expression as prognostic markers in low and intermediate‑1 risk patients with myelodysplastic syndromes.

Kalitin N, Dudina G, Kostritsa N, Sivirinova A, Karamysheva A Oncol Lett. 2023; 25(3):95.

PMID: 36817042 PMC: 9932006. DOI: 10.3892/ol.2023.13681.

Myelodysplastic syndrome with synchronous gastric cancer: when the symptoms suggest something else.

Campos P, Traina F, Lorand-Metze I, Olalla Saad S Rev Bras Hematol Hemoter. 2014; 36(6):442-4.

PMID: 25453656 PMC: 4318472. DOI: 10.1016/j.bjhh.2014.07.005.

References

Chen C, Lin L, Tang J, Ko B, Tsay W, Chou W . RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol. 2007; 139(3):405-14. DOI: 10.1111/j.1365-2141.2007.06811.x. View

Odenike O, Le Beau M . The dawn of the molecular era of the myelodysplastic syndromes. N Engl J Med. 2011; 364(26):2545-6. DOI: 10.1056/NEJMe1102921. View

Fairman J, Chumakov I, Chinault A, Nowell P, Nagarajan L . Physical mapping of the minimal region of loss in 5q- chromosome. Proc Natl Acad Sci U S A. 1995; 92(16):7406-10. PMC: 41348. DOI: 10.1073/pnas.92.16.7406. View

Nikoloski G, Langemeijer S, Kuiper R, Knops R, Massop M, Tonnissen E . Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010; 42(8):665-7. DOI: 10.1038/ng.620. View

Steensma D, Dewald G, Lasho T, Powell H, McClure R, Levine R . The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005; 106(4):1207-9. PMC: 1895198. DOI: 10.1182/blood-2005-03-1183. View

Shannon K, Le Beau M . Cancer: hay in a haystack. Nature. 2008; 451(7176):252-3. DOI: 10.1038/451252a. View

Barlow J, Drynan L, Hewett D, Holmes L, Lorenzo-Abalde S, Lane A . A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med. 2009; 16(1):59-66. PMC: 2803774. DOI: 10.1038/nm.2063. View

Boultwood J, Fidler C, Strickson A, Watkins F, Gama S, Kearney L . Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood. 2002; 99(12):4638-41. DOI: 10.1182/blood.v99.12.4638. View

Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X . DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2009; 28(4):605-13. PMC: 2815995. DOI: 10.1200/JCO.2009.23.4781. View

10.

Zhao N, Stoffel A, Wang P, Eisenbart J, Espinosa 3rd R, Larson R . Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci U S A. 1997; 94(13):6948-53. PMC: 21265. DOI: 10.1073/pnas.94.13.6948. View

11.

Christiansen D, Andersen M, Pedersen-Bjergaard J . Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2003; 17(9):1813-9. DOI: 10.1038/sj.leu.2403054. View

12.

Loh M, Vattikuti S, Schubbert S, Reynolds M, Carlson E, Lieuw K . Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood. 2003; 103(6):2325-31. DOI: 10.1182/blood-2003-09-3287. View

13.

Rosati S, Mick R, Xu F, Stonys E, Le Beau M, Larson R . Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome. Leukemia. 1996; 10(1):20-6. View

14.

Kurtin P, Dewald G, Shields D, Hanson C . Hematologic disorders associated with deletions of chromosome 20q: a clinicopathologic study of 107 patients. Am J Clin Pathol. 1996; 106(5):680-8. DOI: 10.1093/ajcp/106.5.680. View

15.

Jadersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Gohring G . TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2011; 29(15):1971-9. DOI: 10.1200/JCO.2010.31.8576. View

16.

Sekeres M, Schoonen W, Kantarjian H, List A, Fryzek J, Paquette R . Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 2008; 100(21):1542-51. PMC: 2579314. DOI: 10.1093/jnci/djn349. View

17.

Tehranchi R, Woll P, Anderson K, Buza-Vidas N, Mizukami T, Mead A . Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med. 2010; 363(11):1025-37. DOI: 10.1056/NEJMoa0912228. View

18.

Chen T, Kambal A, Krysiak K, Walshauser M, Raju G, Tibbitts J . Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice. Blood. 2010; 117(5):1530-9. PMC: 3056590. DOI: 10.1182/blood-2010-06-293167. View

19.

Rowley J, Reshmi S, Sobulo O, Musvee T, Anastasi J, Raimondi S . All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood. 1997; 90(2):535-41. View

20.

Baron V, Adamson E, Calogero A, Ragona G, Mercola D . The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther. 2005; 13(2):115-24. PMC: 2455793. DOI: 10.1038/sj.cgt.7700896. View